Search hospitals > Quebec > MONTREAL
Maisonneuve-Rosemont Hospital
Claim this profileMONTREAL, Quebec H1T 2M4
Global Leader in Leukemia
Global Leader in Breast Cancer
Conducts research for Cancer
Conducts research for Myeloid Leukemia
Conducts research for Acute Myeloid Leukemia
317 reported clinical trials
26 medical researchers
Summary
Maisonneuve-Rosemont Hospital is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Leukemia, Breast Cancer, Cancer, Myeloid Leukemia, Acute Myeloid Leukemia and other specialties. Maisonneuve-Rosemont Hospital is involved with conducting 317 clinical trials across 375 conditions. There are 26 research doctors associated with this hospital, such as Michael Yassa, Jonathan Noujaim, Dr. Mai-Kim Gervais, and Veronique Brulotte, MD, MSc.Area of expertise
1Leukemia
Global LeaderBCR/ABL negative
NPM1-m positive
CD33 positive
2Breast Cancer
Global LeaderHER2 negative
ER positive
HER2 positive
Top PIs
Michael YassaMaisonneuve-Rosemont Hospital5 years of reported clinical research
Studies Breast Cancer
Studies Radiotherapy
5 reported clinical trials
7 drugs studied
Jonathan NoujaimGSK Investigational Site1 year of reported clinical research
Studies Tumors
Studies Breast Cancer
5 reported clinical trials
13 drugs studied
Dr. Mai-Kim GervaisHopital Maisonneuve-Rosemont3 years of reported clinical research
Studies Skin Cancer
Studies Melanoma
3 reported clinical trials
5 drugs studied
Veronique Brulotte, MD, MScMaisonneuve-Rosemont Hospital1 year of reported clinical research
Studies Chronic Pain
Studies Postoperative Pain
3 reported clinical trials
3 drugs studied
Clinical Trials running at Maisonneuve-Rosemont Hospital
Prostate Cancer
Breast Cancer
Cancer
Bladder Cancer
Leukemia
Acute Myeloid Leukemia
Acute Leukemia
Skin Cancer
Sarcoma
Marginal Zone Lymphoma
Radiotherapy
for High Risk Prostate Cancer
In North America, the number of new cases of prostate cancer increases every year. Many efforts have been made to develop more efficient and safer curative treatments for high risk prostate cancer patients. This phase III clinical trial is designed to compare the safety of a standard pelvic external beam radiation therapy (EBRT) combined with a high dose rate brachytherapy (HDRB) boost (direct insertion of radiation source over a period of minutes via flexible needles temporarily inserted in the prostate) to a shorter course of hypofractionated dose escalation radiotherapy (larger radiation dose per daily treatment) in patients with high risk prostate cancer. The investigators plan to recruit 296 patients across Quebec who will be randomized in either treatment plan.
Recruiting2 awards Phase 39 criteria
Darolutamide + SBRT
for Prostate Cancer
This trial tests a combination of precise radiation therapy and a hormone-blocking drug in prostate cancer patients with limited spread. It aims to control the disease and delay more toxic treatments. The approach targets small areas of cancer spread and blocks the cancer's growth signals. The hormone-blocking drug is a novel treatment approved for specific prostate cancer cases.
Recruiting2 awards Phase 23 criteria
Darolutamide + ADT
for Prostate Cancer
Researchers are looking for a better way to treat men at high-risk of biochemical recurrence (BCR) of prostate cancer. BCR means that in men who had prostate cancer and were treated by either surgery and/ or radiation therapy, the blood level of a specific protein called PSA rises. PSA is a marker of prostate cancer cells activity. The PSA increase means that the cancer has come back even though conventional imaging such as computed tomography (CT) scans, magnetic resonance imaging (MRI) and bone scans does not show any lesion of prostate cancer. Recently a more sensitive imaging method called prostate-specific membrane antigen \[PSMA\] positron emission tomography \[PET\]) /computed tomography \[CT\]) scan may identify prostate cancer lesions not detectable by conventional imaging. Men with BCR have a higher risk of their cancer spreading to other parts of the body, particularly when PSA levels raised to a certain limit within a short period of time after local therapies. Once the cancer spreads to other parts of the body, it can become even harder to treat. In men with prostate cancer, male sex hormones (also called androgens) like testosterone can help the cancer grow and spread. To reduce androgens levels in these patients, there are treatments that block androgens production in the body called androgen deprivation therapy (ADT). ADT is often used to stop prostate cancer. Another way to stop prostate cancer growth and spread is to block the action of androgen receptors on prostate cancer cells called androgen receptor inhibitors (ARIs). The new generation ARIs including darolutamide can block the action of androgens receptors and are available for the treatment of prostate cancer in addition to ADT. It is already known that men with prostate cancer benefit from these treatments. The main objective of this study is to learn if the combination of darolutamide and ADT prolongs the time that the participants live without their cancer getting worse, or to death due to any cause, compared to placebo (which is a treatment that looks like a medicine but does not have any medicine in it) and ADT given for a pre-specified duration of 24 months. To do this, the study team will measure the time from the date of treatment allocation to the finding of new cancer spread in the participants by using PSMA PET/CT, or death due to any cause. The PSMA PET/CT scans is performed using a radioactive substance called a "tracer" that specifically binds to the prostate-specific membrane antigen (PSMA) which is a protein often found in large amounts on prostate cancer cells. To avoid bias in treatment, the study participants will be randomly (by chance) allocated to one of two treatment groups. Based on the allocated treatment group, the participants will either take darolutamide plus ADT or placebo plus ADT twice daily as tablets by mouth. The study will consist of a test (screening) phase, a treatment phase and a follow-up phase. The treatment duration is pre-specified to be 24 months unless the cancer gets worse, the participants have medical problems, or they leave the study for any reason. In addition, image guided radiotherapy (IGRT) or surgery is allowed and your doctor will explain the benefits and risks of this type of therapy. During the study, the study team will: * take blood and urine samples. * measure PSA and testosterone levels in the blood samples * do physical examinations * check the participants' overall health * examine heart health using electrocardiogram (ECG) * check vital signs * check cancer status using PSMA PET/CT scans, CT, MRI and bone scans * take tumor samples (if required) * ask the participants if they have medical problems About 30 days after the participants have taken their last treatment, the study doctors and their team will check the participants' health and if their cancer worsened. The study team will continue to check this and regularly ask the participants questions about medical problems and subsequent therapies until they leave the study for any reason or until they leave the study for any reason or until the end of the study, whatever comes first.
Recruiting1 award Phase 3
Similar Hospitals nearby
Select from list below to view details
Frequently asked questions
What kind of research happens at Maisonneuve-Rosemont Hospital?
Maisonneuve-Rosemont Hospital is a medical facility located in MONTREAL, Quebec. This center is recognized for care of Leukemia, Breast Cancer, Cancer, Myeloid Leukemia, Acute Myeloid Leukemia and other specialties. Maisonneuve-Rosemont Hospital is involved with conducting 317 clinical trials across 375 conditions. There are 26 research doctors associated with this hospital, such as Michael Yassa, Jonathan Noujaim, Dr. Mai-Kim Gervais, and Veronique Brulotte, MD, MSc.
Where is Maisonneuve-Rosemont Hospital located?
**Maisonneuve-Rosemont Hospital**
- **Address:** 5415 Boulevard de l'Assomption, Montreal, Quebec.
- **Accessibility:** The hospital is about a 13-minute walk from Station Viau, the nearest metro station.
Who should I call to ask about financial aid or insurance network?
**Maisonneuve-Rosemont Hospital Financial and Insurance Services**
**Financial Services:**
- CIUSSS EMTL - Exclusifs benefits - Financial services - Beneva
**Insurance and Financial Services:**
- Agency: Montréal Maisonneuve, iA Financial Group
- Location: 6555 Métropolitain Blvd. E, Unit 403, Saint-Léonard, Quebec, H1P 3H3
- Contact: 514-324-3811, Toll-free: 1-866-324-3811, Fax: 1-877-781-7413
- Hours: Mon-Fri, 8:30 am - 4:30 pm
**Public Health Insurance and Prescription Drug Insurance Plans:**
- Provider: Régie de l'assurance maladie du Québec (RAMQ)
- Contact: Québec: 418 646-4636, Montréal: 514 864-3411, Toll-free: 1 800 561-9749, Outside Québec: 514 864-3411
- Hours: Mon-Fri, 8:30 am - 4:30 pm
What insurance does Maisonneuve-Rosemont Hospital accept?
Maisonneuve-Rosemont Hospital is part of the Centre intégré universitaire de santé et de services sociaux (CIUSSS) de l’Est-de-l’Île-de-Montréal. It is affiliated with Université de Montréal and welcomes over 4,000 students annually. For detailed information about accepted insurance plans, it is recommended to contact the hospital directly or visit their official website.
What awards or recognition has Maisonneuve-Rosemont Hospital received?
Maisonneuve-Rosemont Hospital, located in Montreal, Quebec, is renowned for its excellence in immunology-oncology, nephrology, and vision health. Its research center, CR-HMR, is globally recognized for pioneering clinical therapies and vibrant academic endeavors. The hospital leads in cellular therapy, innovating treatments for incurable diseases within its areas of excellence.